Kenvue Inc. (NYSE:KVUE) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. trimmed its position in Kenvue Inc. (NYSE:KVUE) by 35.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 1,527,592 shares of the company’s stock after selling 835,667 shares during the period. Russell Investments Group Ltd.’s holdings in Kenvue were worth $32,614,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Envestnet Asset Management Inc. lifted its holdings in Kenvue by 79.4% during the 4th quarter. Envestnet Asset Management Inc. now owns 10,224,056 shares of the company’s stock worth $218,284,000 after buying an additional 4,523,918 shares during the last quarter. Aviva PLC raised its position in shares of Kenvue by 1,159.8% during the 4th quarter. Aviva PLC now owns 1,154,701 shares of the company’s stock worth $24,653,000 after acquiring an additional 1,063,043 shares in the last quarter. Resona Asset Management Co. Ltd. purchased a new stake in Kenvue during the fourth quarter worth approximately $13,601,000. Prudential PLC boosted its holdings in Kenvue by 1,699.1% in the fourth quarter. Prudential PLC now owns 574,143 shares of the company’s stock valued at $12,258,000 after purchasing an additional 542,231 shares in the last quarter. Finally, Huber Capital Management LLC increased its stake in Kenvue by 15.6% in the fourth quarter. Huber Capital Management LLC now owns 169,300 shares of the company’s stock valued at $3,615,000 after purchasing an additional 22,900 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

NYSE:KVUE opened at $21.76 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a market cap of $41.58 billion, a price-to-earnings ratio of 41.05, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. The firm’s fifty day moving average price is $22.60 and its 200 day moving average price is $22.45. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.77%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is 154.72%.

Analyst Ratings Changes

Several research analysts have recently issued reports on KVUE shares. UBS Group lowered their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Piper Sandler lifted their target price on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Evercore ISI initiated coverage on Kenvue in a research report on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price for the company. Finally, Barclays lifted their price target on Kenvue from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and a consensus price target of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.